You are correct, 3/3 and 5/5 refers to CDH17, and so do the dose levels I have listed (50, 150 and 450).
Ash mentions the following:
"Study treatment: Patients will receive Aza/Ven as standard. Two dose levels of NK cells including 0.5 x10^9 and 1 x10^9 flat dose on day 8 and 15 of the first 4 cycles will be evaluated. Subsequently, pts will continue Aza/Ven indefinitely."
https://ashpublications.org/blood/article/142/Supplement%201/4863/505848/Azacitidine-Venetoclax-and-Allogeneic-NK-Cells-in
Only 2 dose levels, 6-12 patients:
You are correct, 3/3 and 5/5 refers to CDH17, and so do the dose...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |